Legendary heroine Lara Croft returns in Tomb Raider: Catalyst, the all-new major entry in the Tomb…
Blog
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering…
Spotlight Energy Closes on Acquisition of PathPoint Energy
Leading U.S. Trader Expands Its North American Natural Gas Trading and Optimization Platform HOUSTON–(BUSINESS WIRE)–#OnePWRSolutions—Spotlight Energy,…
Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor
RICHMOND, Va.–(BUSINESS WIRE)–$MO #Altria–Altria Group, Inc. (Altria) (NYSE: MO) announces today that Billy Gifford, Altria’s Chief…
Ciena Reports Fiscal Fourth Quarter 2025 and Year-End Financial Results
Summary Fiscal fourth quarter 2025 revenue was $1.35 billion, up 20% year-over-year Fiscal year 2025 revenue…
Management of VIA optronics Holding AG Acquires Majority Stake of the Company
NUREMBERG, Germany–(BUSINESS WIRE)–#CameraTechnologies–VIA optronics Holding AG (OTC: VIAOY) (“VIA” or the “Company”), a leading supplier of…
Manchester United PLC Reports First Quarter Fiscal 2026 Results
Key Points Achieved total revenues of £140.3 million and adjusted EBITDA of £26.9 million, compared to…
Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth
MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the «Company» or «Covalon») (TSXV: COV; OTCQX: CVALF), an advanced medical…
Consor Engineers Appoints Patrick Cassity as President and Chief Executive Officer
MIAMI–(BUSINESS WIRE)–#AECindustry–Consor Engineers (“Consor”), a leading North American engineering and advisory firm at the forefront of…
Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil
Registration-directed program also includes a second Phase 3 trial in males and a Phase 2/3 trial…